Erratum: Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial (Lancet (2014) 383 (515-23))

E. Lawitz; F. F. Poordad; P. S. Pang

Erratum: Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial (Lancet (2014) 383 (515-23))

Resultado de la investigación: Comment/debate › revisión exhaustiva

Idioma original	English (US)
Páginas (desde-hasta)	870
Número de páginas	1
Publicación	The Lancet
Volumen	383
N.º	9920
Estado	Published - 2014

ASJC Scopus subject areas

Medicine(all)

Otros archivos y enlaces

Citar esto

Erratum : Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial (Lancet (2014) 383 (515-23)). / Lawitz, E.; Poordad, F. F.; Pang, P. S.

En: The Lancet, Vol. 383, N.º 9920, 2014, p. 870.

Resultado de la investigación: Comment/debate › revisión exhaustiva

@article{1995cf688a834e2a87569d16823e481d,

title = "Erratum: Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial (Lancet (2014) 383 (515-23))",

author = "E. Lawitz and Poordad, {F. F.} and Pang, {P. S.}",

year = "2014",

language = "English (US)",

volume = "383",

pages = "870",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "9920",

}

TY - JOUR

T1 - Erratum

T2 - Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial (Lancet (2014) 383 (515-23))

AU - Lawitz, E.

AU - Poordad, F. F.

AU - Pang, P. S.

PY - 2014

Y1 - 2014

UR - http://www.scopus.com/inward/record.url?scp=84897724852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897724852&partnerID=8YFLogxK

M3 - Comment/debate

AN - SCOPUS:84897724852

SN - 0140-6736

VL - 383

SP - 870

JO - The Lancet

JF - The Lancet

IS - 9920

ER -